Peroxisome proliferator-activated receptors from orphanage to fame in a decade

Saudi Pharmaceutical Journal

Volumn 9, Issue 1, 2001, Pages 1-13

  Youssef, J A ^a   Badr, M Z ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA 12,14 PROSTAGLANDIN J2; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; ARACHIDONIC ACID; CIGLITAZONE; DELTA12 PROSTAGLANDIN J2; GW 2331; LEUKOTRIENE B4; LIGAND; LINOLEIC ACID; OLEIC ACID; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PIRINIXIC ACID; RECEPTOR SUBTYPE; ROSIGLITAZONE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ATHEROSCLEROSIS; CANCER; CHEMICAL STRUCTURE; DIABETES MELLITUS; DRUG MECHANISM; FERTILITY; HUMAN; INFLAMMATION; OBESITY; PEROXISOME; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN INDUCTION; RECEPTOR GENE; RECEPTOR UPREGULATION; REVIEW;

EID: 0034983634     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Hepatic peroxisome proliferation in rodents and its significance for humans
2. Correlated morphometric and biochemical studies on the rat liver cell II: Effects of phenobarbital on rat hepatocytes
3. Correlated morphometric and biochemical studies of the rat liver I: Morphometric model, stereologic methods and normal morphometric data for rat liver
4. Biogenesis of peroxisomes
5. Peroxisome structure, function and biogenesis: Human patients and yeast mutants show strinkingly similar defects in peroxisome biogenesis
6. How proteins penetrate peroxisomes
7. A new cellular function for peroxisomes related to oxygen free radicals
8. Metabolic pathways in peroxisomes and glyoxysomes
9. On the role of the peroxisome in ontogeny, aging and degenerative disease
10. Extraperoxisomal targets of peroxisome proliferators: Mitcochondrial, microsomal and cytosolic effects, implications for health and disease
11. Biology of senescent liver peroxisomes: Role in hepatocellular aging and disease
12. Biochemistry of peroxisomes
13. Experimental studies on the toxicity of atromid with particular reference to fine structural changes in the livers of rodents
14. Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment
15. Hepatic peroxisomal changes induced by tetrazole-substituted alkoxyacetophenone in rats and comparison with other species
16. Concomitant induction of cytosolic apoxide hydrolase and peroxisomal β-oxidation by hypolipidemic compounds in rats and guinea pig liver
17. Comparative studies on nafenopin-induced hepatic perosixome proliferation in the rat, syrian hamster, guinea pig and marmaset
18. Species differences in the effect of bezafibrate, a hypolipidemic agent on hepatic peroxisome - Associated enzymes
19. Comparison of the inducing effect of dehydroepiandrosterone on hepatic peroxisome proliferation-associated enzymes in several rodent species
20. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
21. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
22. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
23. The PPARs: From orphan receptors to drug discovery
24. cDNA Cloning, chromosomal mapping and functional characterization of the human peroxisome proliferator-activated receptor
25. Human and rat peroxisome proliferator-activated receptors (PPARs) demonestrate similar tissue distribution but different responsiveness to PPAR activators
26. Isolation of the human peroxisome proliferator-activated receptor gamma cDNA: Expression in hematopoitic cells and chromosomal mapping
27. Monitoring of PPAR alpha protein expression in human tissue by the use of PPAR alpha-specific mab
28. Terminal differentiation of human breast cancer through PPARγ
29. Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions
30. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
31. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptors γ and the reinoid X receptor
32. Peroxisome proliferator activated receptor agonists
33. The PPARα-Leukotriene B4 pathway to inflammation control
34. Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ
35. Fatty acids bind to and activate peroxisome proliferator-activated receptors α and δ
36. Fatty acids in control of gene expression
37. Peroxisome biogenesis disorders: Identification of a new complementation group distinct from peroxisome-deficient CHO mutants and not complemented by human PEX 13
38. Peroxisomal disorders: A newly recognized group of genetic disease
39. Biochemistry of peroxisomes in health and disease
40. Phenotype of patients with peroxisomal disorders subdivided into 16 complementation groups
41. Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome
42. Lignoceric acid is oxidized in the peroxisomes, implications for the Zellweger cerebro-hepato-renal syndrome and adrenaleukodystrophy
43. Rhrzometic Chondrodysplasia Punctata: Biochemical studies of peroxisomes isolated from cultured skin fibroblasts
44. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor
45. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydrox-3-methylglutaryl-CoA synthase gene by fatty acids
46. The Peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression
47. Human liver lauric acid hydroxylase activities
48. The peroxisome proliferator-activated receptor regulates malic enzyme gene expression
49. Induction of peroxisomal enzyme activities by diethylhexylphthalate in thyroidectomized rats with parathyroid replants
50. Regulation of the peroxisomal β-oxidation-dependent pathway by peroxisome proliferator-activated receptor α and kinases
51. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis
52. Roles of PPARs in health and disease
53. Peroxisome proliferator-activated receptors: Insight into multiple cellular functions
54. Age Changes in signal transduction and gene expression
55. On the Role of the peroxisome in ontogeny, aging and degenerative disease
56. Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis
57. Aging decreases retinoic acid and triiodothyronine nuclear expresson in rat liver, exogenous retinol and retinoic acid differentially modulates this decreased expression
58. The adrenocortical stress response in the aged male rat: Impairment of recovery from stress
59. Do Vasoprossin-related peptides induce hippocampal corticosterone receptors? Implications for aging
60. Spatial orientation and the hippocampal corticosterone receptor system of old rats: Effect of ACTH 4-9 analogue ORG2766
61. Regulation of the peroxisome proliferator-activated receptor α gene by glucocorticoids
62. Conclusive Evidence that very long chain fatty acids are oxidized exclusively in peroxisomes in human skin fibroblasts
63. The role of membrane structure and function in cellular aging: A review
64. Age-related disease in liver peroxisomal fatty acid oxidation in control and clofibratetreated mice, a biochemical study and mechanistic approach
65. Membrane alterations as causes of impaired signal transduction in Alzheiemr's disease and aging
66. The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function
67. Peroxisome proliferator-activated receptor gene expression in human tissues effects of obesity, weight loss and regulation by insulin and glucocorticoids
68. Depot-specific differences in adipose tissue gene expression in lean and obese subjects
69. Adipogenesis and obesity: Rounding out the big picture
70. Differential activation of adipogenesis by multiple PPAR isoforms
71. Hypolipdemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors α and d
72. A Prostaglandin J2 metabolite binds to peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
73. PPARγ in Monocytes: Less pain, any gain
74. Beyond Cholesterol modification of low-density lipoprotein that increase its atherogenecity
75. PPARγ Promotes monocyte/macrophage differentiation and uptake of oxidized LDL
76. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human athersclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
77. Macrophages in human atheroma contain PPARγ differentiation dependent peroxisome proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro
78. Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor κB to DNA and the subsequent expression of tumor necrosis factor-α and interleukin-1β in macrophages
79. Oxidants, antioxidants and degenerative diseases of aging
80. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis
81. Dietary n-3 fatty acids accelerate catabolism of leukotriene B4 in human granulocytes
82. Induction of peroxisomal enzymes and a 64 kDa peptide in cultured couse macrophages treated with clofibrate
83. Peroxisome proliferator-activated receptor alpha activation modulates. Cellular redox status, represses nuclear factor-kappa B signalling, and reduces inflammatory cytokine production in aging
84. The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation
85. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal-anti-inflammatory drugs
86. The aging process
87. Do Peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?
88. Induction of replicative DNA synthesis and PPARcα-dependent gene transcription by WY-14,643 in primary rat hepatocyte and non-parenchymal cell co-culture
89. Evidence for the suppression of apoptosis by the peroxisome proliferator-activated receptor alpha (PPARα)
90. Mechanisms and functions of cell death
91. Suppression of liver apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin
92. Non-genotoxic hepatocarcinogen stimulate DNA synthesis and their withdrawal induces apoptosis but in different hepatocyte populations
93. Activation of the nuclear receptor PPARγ enhances colon polyps formation
94. Differentiation and reversal of malignant changes in colon cancer through PPARγ
95. PPARγ and Colorectal carcinoma: Conflicts in a nuclear family
96. PPARδ is an APC-Regulated Target of nonsteroidal antiinflammatory drugs
97. Cyclooxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ